Rhythm plans Phase III trial design discussions with the FDA and EMA and in-licensed bivamelagon from LG Chem.
2 reports, 1 independent
Updated Jul 10
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rhythm plans Phase III trial design discussions with the FDA and EMA and in-licensed bivamelagon from LG Chem.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
EMA
Japanese vocalist of the group DUSTCELL
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaRhythm’s stock climbs on encouraging Phase II obesity drug data Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass ind
- Unknown outlet